tiprankstipranks
Advertisement
Advertisement

CAPR Stock Latest News

Capricor Therapeutics management to meet with Oppenheimer
The FlyCapricor Therapeutics management to meet with Oppenheimer
5d ago
CAPR
Capricor’s Earnings Call: Deramiocel Drives High-Stakes Pivot
PremiumCompany Announcements
Capricor’s Earnings Call: Deramiocel Drives High-Stakes Pivot
1M ago
CAPR
CAPR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
CAPR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
1M ago
CAPR
Capricor Faces Revenue Risk as Dependence on Nippon Shinyaku Puts Deramiocel Commercialization in Jeopardy
PremiumCompany Announcements
Capricor Faces Revenue Risk as Dependence on Nippon Shinyaku Puts Deramiocel Commercialization in Jeopardy
1M ago
CAPR
Capricor Therapeutics price target lowered to $38 from $43 at Roth Capital
PremiumThe Fly
Capricor Therapeutics price target lowered to $38 from $43 at Roth Capital
1M ago
CAPR
Analyst Reiterates Buy on Capricor Ahead of Key 2026 PDUFA, Maintains $60 Price Target
PremiumRatingsAnalyst Reiterates Buy on Capricor Ahead of Key 2026 PDUFA, Maintains $60 Price Target
1M ago
CAPR
FDA Commissioner Marty Makary resigns
Premium
The Fly
FDA Commissioner Marty Makary resigns
1M ago
AZN
BMY
Capricor Therapeutics options imply 9.4% move in share price post-earnings
Premium
The Fly
Capricor Therapeutics options imply 9.4% move in share price post-earnings
1M ago
CAPR
Capricor Buy Rating Reiterated on Deramiocel Opportunity and NS Pharma Dispute Dynamics; $50 Price Target Maintained
PremiumRatings
Capricor Buy Rating Reiterated on Deramiocel Opportunity and NS Pharma Dispute Dynamics; $50 Price Target Maintained
1M ago
CAPR
Capricor files suit against NS Pharma over Deramiocel distribution deal
PremiumThe Fly
Capricor files suit against NS Pharma over Deramiocel distribution deal
1M ago
CAPR
Capricor Sues NS Pharma Over Deramiocel U.S. Rights
PremiumCompany Announcements
Capricor Sues NS Pharma Over Deramiocel U.S. Rights
1M ago
8K
CAPR
3 ‘Perfect 10’ Smart Score Stocks to Buy this Week, 3/30/26, According to Analysts
PremiumMarket News
3 ‘Perfect 10’ Smart Score Stocks to Buy this Week, 3/30/26, According to Analysts
3M ago
XEL
CAPR
Capricor Therapeutics price target raised to $43 from $41 at Roth Capital
PremiumThe FlyCapricor Therapeutics price target raised to $43 from $41 at Roth Capital
3M ago
CAPR
Capricor Therapeutics Nears Key Milestones After Earnings Call
Premium
Company Announcements
Capricor Therapeutics Nears Key Milestones After Earnings Call
3M ago
CAPR
Capricor selloff today a buying opportunity, says Roth Capital
Premium
The Fly
Capricor selloff today a buying opportunity, says Roth Capital
3M ago
CAPR
Capricor Therapeutics price target raised to $51 from $48 at Alliance Global
PremiumThe Fly
Capricor Therapeutics price target raised to $51 from $48 at Alliance Global
3M ago
CAPR
Capricor Therapeutics price target raised to $63 from $50 at B. Riley
PremiumThe Fly
Capricor Therapeutics price target raised to $63 from $50 at B. Riley
3M ago
CAPR
Capricor Therapeutics price target raised to $58 from $45 at Piper Sandler
PremiumThe Fly
Capricor Therapeutics price target raised to $58 from $45 at Piper Sandler
3M ago
CAPR
Capricor Therapeutics reports Q4 EPS (62c), consensus (55c)
PremiumThe Fly
Capricor Therapeutics reports Q4 EPS (62c), consensus (55c)
3M ago
CAPR
Capricor Therapeutics options imply 4.2% move in share price post-earnings
PremiumThe FlyCapricor Therapeutics options imply 4.2% move in share price post-earnings
3M ago
CAPR
Deramiocel’s De‑Risked Path to Approval and Expanded DMD Opportunity Underpin Buy on CAPR
Premium
Ratings
Deramiocel’s De‑Risked Path to Approval and Expanded DMD Opportunity Underpin Buy on CAPR
3M ago
CAPR
Capricor announces additional analyses, outcomes from Phase 3 HOPE-3 trial
Premium
The Fly
Capricor announces additional analyses, outcomes from Phase 3 HOPE-3 trial
3M ago
CAPR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >